

MOTIV[®]


Tyrocore[®] Peripheral Vascular
Bioresorbable Scaffold

The Most Advanced DRS

Tyrocore Strength Enables Thin Struts with Best-in-Class Scaffold Performance



Thin struts with best-in-class strength for rapid healing and sustained patency

Size	Strut Thickness	
	Esprit	MOTIV
2.5 mm	99 μ m	95 μ m
3.0 mm	99 μ m	105 μ m
3.5 mm	120 μ m	115 μ m
4.0 mm	n/a	125 μ m





A New Era for DRS Deliverability

Full radiopacity ensures precise placement






Improved ease-of-use during implant procedure



Rapid Vessel Healing, Benign Resorption

**Demonstrated
with Tyrocore DRS**



MOTIV Performance Characteristics

Characteristic	MOTIV	Esprit
Scaffold material	Tyrocore	PLLA
Drug coating	Sirolimus + Tyrocore	Everolimus + PDLLA
Strut thickness	2.5 mm, 95 µm 3.0 mm, 105 µm 3.5 mm, 115 µm 4.0 mm, 125 µm	2.5-3.0 mm, 99 µm 3.5-3.75 mm, 120 µm
Lengths	12, 18, 24, 36, 48, 60 mm	18, 28, 38 mm
Delivery	Single-step inflation	Multi-step inflation
Radial strength^{2,3}	0.22 N/mm	0.13 N/mm
Max expansion over nominal	+0.75 mm, 2.5-3.0 mm diam +0.5 mm, 3.5-4.0 mm diam	+0.5 mm
Resorption profile	Vessel uncaged in 1 year Resorption in ~3-4 years	Loss of mechanical support in ~6 months Resorption in ~3-4 years

MOTIV Ordering Information

MOTIV Sirolimus-Eluting Bioresorbable Vascular Scaffold System

	12 mm	18 mm	24 mm	36 mm	48 mm	60 mm
2.5 mm	920025-12	920025-18	920025-24	920025-36	920025-48	920025-60
3.0 mm	920030-12	920030-18	920030-24	920030-36	920030-48	920030-60
3.5 mm	920035-12	920035-18	920035-24	920035-36	920035-48	920035-60
4.0 mm	920040-12	920040-18	920040-24	920040-36	920040-48	

References

1. Product Instructions for Use.
2. Manufacturer reported data on file at REVA Medical.
3. 3.0 mm diameter scaffolds. Tests performed by and data on file at REVA Medical. Bench testing in water at 37°C. Radial Strength measured at 15% compression.
4. Abizaid, A. New 24-month data from the FANTOM II clinical trial. EuroPCR 2018.
5. Abizaid, A. The FANTOM II study, first report for the 12-month clinical outcomes of the Fantom sirolimus-eluting bioresorbable scaffold. EuroPCR 2018.

REVA Medical European Authorized Representative: REVA Germany GmbH Karpfenweg 12 60327 Frankfurt am Main Germany.

Customer Service: TEL: +31 73 303 2559, FAX: +31 73 369 0551, EMAIL: revamedical@healthlinkeurope.com.

MOTIV is available in select countries that accept CE Mark. MOTIV is not available in the U.S.

MOTIV and Tyrocore are trademarks of REVA Medical, LLC. REVA Medical, LLC, 5751 Copley Drive, San Diego, CA, 92111, United States of America.

Absorb is a trademark of Abbott. Magmaris is a trademark of Biotronik.

www.revamedical.com

©2026 REVA Medical, LLC. CC100098 Rev. C



REVA